Post-Market Clinical Follow-up (PMCF) Surveys

Rigorous, regulator-ready PMCF survey programmes designed by medtech research specialists. From study design to final report, we generate the clinical evidence your Notified Body expects.

EU MDR 2017/745 · ANNEX XIV

What is PMCF — and why does it matter?

PMCF surveys are the most practical and cost-efficient route to generating this evidence — directly feeding your PMCF report, Clinical Evaluation Report (CER), and PSUR documentation.

Post-Market Clinical Follow-up (PMCF) is a mandatory, ongoing regulatory process for all CE-marked medical devices. It requires manufacturers to proactively collect and evaluate real-world clinical data to confirm the continued safety and performance of their device throughout its lifecycle.

A regulatory requirement — and a strategic asset

Under EU MDR 2017/745, Post-Market Clinical Follow-up is a mandatory, ongoing process for all CE-marked medical devices. PMCF surveys represent one of the most practical and cost-efficient routes to generating the real-world clinical evidence your technical documentation demands.

Beyond compliance, well-designed PMCF data provides genuine commercial intelligence — confirming device performance, identifying emerging risks early, and strengthening your benefit-risk case at each Notified Body audit.

EU MDR Article 61 & Annex XIV

PMCF is required for all device classes unless a scientific justification confirms it is unnecessary. For Class IIa, IIb, and III devices, and those approved via equivalence or with limited long-term safety data, PMCF surveys are typically the most appropriate evidence-generation activity.

PMCF surveys are particularly applicable where:

  • Clinical evidence from pre-market was generated via equivalence

  • The device uses novel or emerging technology

  • Long-term safety and performance data is limited

  • The device is used in high-risk or vulnerable patient populations

  • Your Notified Body has requested additional real-world evidence

  • Post-market surveillance has flagged unresolved safety signals

Two evidence levels. One specialist team.

LEVEL 4 EVIDENCE

Case-Specific Clinical Surveys

The highest-quality survey evidence under MDR. Completed per patient case by treating clinicians using medical records or charts.

  • Prospective or retro/prospective data collection

  • Minimises recall bias — reflects real clinical encounters

  • Supports device-level, variant & subgroup analysis

  • Accepted by TÜV SÜD, BSI and other leading NBs

Our Approach

End-to-end delivery, built around your device

From gap analysis to final regulatory report, medintel manages every stage. Each project is led by a dedicated research specialist with hands-on medtech experience.

Gap Analysis & Strategy

We review your PMCF plan and CER to identify clinical data gaps and define the optimal survey approach for your device and Notified Body.

Survey & Protocol Design

MDCG-compliant PMCF plan, questionnaire design, sample size determination, screener development, and SAS plan.

LEVEL 8 EVIDENCE

General End-User Surveys

A cost-effective, widely accepted method for lower-risk devices or as a complementary data source alongside higher-level evidence.

  • Retrospective HCP feedback on device experience

  • Rapid deployment — ideal for annual PMCF cycles

  • Validated questionnaire aligned with your PMCF plan

  • Suitable for Class I & IIa devices, legacy products

Fieldwork & Data Collection

Recruitment of authenticated HCPs, secure online data collection, ongoing quality checks, and response rate management throughout fieldwork.

Statistical Analysis

Full statistical analysis and data tables in line with your pre-specified SAS plan. Raw data quality auditing and clean dataset delivery.

PMCF Survey Report

MDCG 2020-8 compliant report, ready to integrate directly into your CER, risk management file, and PSUR documentation.

Why choose medintel for PMCF?

Specialist medtech expertise at every stage

Deep Therapeutic Area Knowledge

First-hand experience across cardiovascular, vascular intervention, surgical, orthopaedic, and diagnostic devices — we understand the clinical context behind every question.

Verified HCP Panels

Curated panels of authenticated healthcare professionals actively using your device type in clinical practice. Not generic pools — specialist respondents.

Regulator-Ready Documentation

Every deliverable structured to meet Notified Body expectations. Plans, reports, and statistical outputs accepted by BSI, TÜV SÜD, and other leading NBs.

Multinational Study Execution

Multilingual PMCF programmes across EU5 and beyond — translation, country-level recruitment, and local regulatory considerations in one coordinated project.

GDPR-First Data Governance

Informed consent, data traceability, anonymisation, and retention protocols aligned with ISO 14155:2020 — built in from study initiation.

Integrated Qualitative Capability

Where quantitative PMCF data raises questions, our in-house qualitative team adds HCP depth interviews — unique contextual insight no pure survey provider offers.

Compliance & Quality Standards

Built To Satisfy Notified Body Scrutiny

EU MDR 2017/745

Annex XIV PMCF requirements and MDCG 2020-7/8 guidance compliance throughout.

ISO 14155:2020

GCP-aligned data collection protocols for clinical investigations of medical devices.

GDPR & ICH-GCP

Informed consent, data minimisation, and traceability built in from study initiation.

Our quality management processes and documentation standards are benchmarked against MDCG guidance and validated through successful Notified Body submissions across multiple device types and risk classifications — including Class IIb and Class III devices.

IVDR 2017/746

PMPF survey services for IVD manufacturers meeting IVDR post-market obligations.

  • "We'd had two previous attempts at PMCF surveys with larger CROs that came back with Notified Body queries. medintel redesigned the protocol from scratch and the report sailed through our BSI audit first time. The team clearly understand what NBs actually want to see — not just what the MDCG guidance says."

    Regulatory Affairs Manager, Class IIb implantable device manufacturer (Germany)

  • "Our EU MDR transition timeline was under serious pressure. MedIntel turned around a Level 4 PMCF survey across five EU countries in fourteen weeks — verified HCPs, clean data, compliant report. That's genuinely faster than anything we'd been quoted elsewhere, without any compromise on quality."

    VP Clinical & Medical Affairs, US-headquartered surgical robotics company (EU MDR transition)

  • "medintel handled our PMCF survey across interventional radiologists in the US and EU simultaneously. The cross-market analysis they produced — not just the regulatory deliverable but the commercial insight layered on top — gave our clinical and marketing teams data they could both use. That dual value is unusual."

    Clinical Evidence Manager, vascular intervention company

Let’s Work Together

If you're interested in a regulatory matter, complete the form with a few details about your project. We'll review your message and get back to you within 48 hours.